Addiction

A new report from VHA shows synthetic opioids have accounted for a significant count of veteran deaths since 2010.

Jonathan Avery, MD, addiction psychiatrist and associate professor of psychiatry, sat down with MD Magazine at APA 2019 to discuss his takeaways and caring for patients with co-occurring mental illness and substance use disorder.

A recent study found that recreational cannabis legalization can lead to increase in car accidents and injuries, but decreases in chronic pain admissions.

A recent study from the Mayo Clinic found that tramadol carries a risk of long-term use similar to that of oxycodone and hydrocodone.

A randomized trial compared cash incentives, peer support, and usual care for increasing rate of HCV treatment among HCV/HIV infected people who use drugs.

A recent study found that black patients were far less likely to be prescribed buprenorphine than white patients.

The lot is being voluntarily recalled due to a detected microbial growth during a routine manufacturing simulation—indicating a potential introduction of microorganisms into the therapy.

Unlike injectable versions, naloxone nasal spray may be administered outside a health care setting by anyone, regardless of medical training.

For expectant parents who smoke, quitting before pregnancy or as early as possible during pregnancy was associated with a reduced risk of preterm birth.

A new Northwell Health study showed that setting a chronic standard-of-care plan and correcting outliers could influence opioid prescription rates.

How a biopsychosocial approach to assessing pain better aligns with the realities of treating pain pathways—and how that can limit opioid depedence.

An extended-release, subcutaneous injection form of buprenorphine (Sublocade) demonstrated long-term efficacy and safety results.

Originally approved in 2002, tegaserod (Zelnorm) was withdrawn in 2007 due to potential safety concerns.

A short account of patients I’ve known and not loved over the years.

Pain management protocols for women undergoing C-sections, that include a non-opioid option such as EXPAREL, can help improve pain management and reduce the need for opioids.

Investigators found that the prevalence of asthma in patients with opioid dependence was more than double the national prevalence.

The soon-to-be marketed therapy Dsuvia has shown enough benefit, tolerability, and safety to aid an at-need patient population in a controlled setting.

Increased opioid prescribing correlated with marketing opioid products to physicians, which subsequently correlated with an increase in mortality from overdoses.

A retrospective study showed which patients with substance use disorder may have less successful antiepileptic drug treatment.

The rate of youths using flavored tobacco products increased by nearly 7% from 2016 to 2017.

A series of recently presented studies support the notion of treating hepatitis C in patients already on opioid substitution therapy.

The Second Chance app from University of Washington investigators is seeking FDA consideration in the near future.

The FDA has approved 2 new dosages of the pain reliever that combines benzhydrocodone and acetaminophen.

New research finds patients face a higher risk of pneumonia if they are taking opioids. The danger is even more pronounced for patients living with HIV.

MD Magazine's most popular stories this year ranged from new clinical insights, to physician-submitted columns, to perspectives on burnout in the workplace.